^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    efavirenz

    i
    Company:
    Generic mfg.
    Drug class:
    Non-nucleoside reverse transcriptase inhibitor
    Apply
    Reverse Triple Negative Immune Resistant Breast Cancer (Renaissance) (NCT05076682)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    10/03/2022
    Initiation :
    06/30/2022
    Primary completion :
    12/01/2022
    Completion :
    03/01/2023
    HER-2 • ZNF689
    |
    HER-2 expression • PGR expression
    |
    AiRuiKa (camrelizumab) • efavirenz